

April 17, 2026

The Honorable Melissa A. Murray  
Chair, Rhode Island Senate Health and Human Services Committee  
82 Smith Street  
Providence, RI 02903

**RE: Support for S2112**

Dear Chair Murray, Vice Chair Lauria, Secretary Urso, and members of the Senate Health and Human Services Committee:

My name is E. Michael Murphy, PharmD, MBA. I am a licensed pharmacist in Ohio and currently serve as a state health policy advisor and faculty member focused on pharmacy practice, insurance design, and patient access to care. I am submitting this testimony in my personal capacity to express strong support for S2112.

While I do not practice in Rhode Island, my work is centered on evaluating how state insurance policies directly affect patient safety, medication adherence, and health care costs. States across the country routinely look to one another when advancing patient-centered health policy, and the issues addressed in these bills are not unique to Rhode Island. As a pharmacist, I have seen firsthand how gaps in coverage for diabetes-related medications and supplies translate into preventable emergencies, avoidable hospitalizations, and tragic outcomes.

S2112 addresses a critical and well-documented patient safety issue by ensuring access to modern, ready-to-use glucagon products without cost-sharing. Hypoglycemia emergencies often occur outside of clinical settings and are frequently managed by family members, caregivers, teachers, or bystanders who are not health professionals. Requiring coverage of glucagon formulations that do not require reconstitution, and eliminating copayments and deductibles, removes a major barrier to timely, life-saving treatment. From both a clinical and policy standpoint, this is a common-sense safeguard that prioritizes outcomes over administrative complexity.

This bill reflects an understanding that diabetes management depends not only on access to insulin, but on access to the full continuum of tools needed to prevent emergencies and maintain stability. They are targeted, evidence-based, and designed to improve adherence while reducing avoidable strain on the health care system.

I commend the sponsors and the Committee for advancing legislation that centers patient safety, affordability, and dignity for individuals and families living with diabetes. I respectfully urge you to support passage of S2112.

Sincerely,

E. Michael Murphy, PharmD, MBA  
Columbus, Ohio